Mario Grassi

Prof. Mario Grassi


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Value in Health
Verified
Journal Article
Closed access
MGMario Grassi
Mario Grassi
ANAndrea Nucera
Andrea Nucera
EZElisabetta Zanolin
Elisabetta Zanolin
EOErnst Omenaas
Ernst Omenaas
JAJosep M. Anto
Josep M. Anto
BLBenedicte Leynaert
Benedicte Leynaert

1 September 2015 in Science of The Total Environment
Verified
Journal Article
Closed access
Alessandro MarconAlessandro Marcon
Alessandro Marcon
GNGiang Nguyen
Giang Nguyen
MRMarta Rava
Marta Rava
MBMarco Braggion
Marco Braggion
MGMario Grassi
Mario Grassi
MZMaria Elisabetta Zanolin
Maria Elisabetta Zanolin

15 June 2023 in Annals of Neurology
Verified
Journal Article
Open access
EZElisabetta Del Zotto
Elisabetta Del Zotto
MGMario Grassi
Mario Grassi
MZMarialuisa Zedde
Marialuisa Zedde
AZAndrea Zini
Andrea Zini
ABAnna Bersano
Anna Bersano
APAlessandro Pezzini
Alessandro Pezzini
Objective: Epidemiological data to characterize the individual risk profile of patients with spontaneous cervical artery dissection (sCeAD) are rather inconsistent.Methods and Results: In the setting of the Italian Project on Stroke in Young Adults Cervical Artery Dissection (IPSYS CeAD), we compared the characteristics of 1,468 patients with sCeAD (mean age = 47.3 ± 11.3 years, men = 56.7%) prospectively recruited at 39 Italian centers with those of 2 control groups, composed of (1) patients whose ischemic stroke was caused by mechanisms other than dissection (non‐CeAD IS) selected from the prospective IPSYS registry and Brescia Stroke Registry and (2) stroke‐free individuals selected from the staff members of participating hospitals, matched 1:1:1 by sex, age, and race. Compared to stroke‐free subjects, patients with sCeAD were more likely to be hypertensive (odds ratio [OR] = 1.65, 95% confidence interval [CI] = 1.37–1.98), to have personal history of migraine with aura (OR = 2.45, 95% CI = 1.74–3.34), without aura (OR = 2.67, 95% CI = 2.15–3.32), and family history of vascular disease in first‐degree relatives (OR = 1.69, 95% CI = 1.39–2.05), and less likely to be diabetic (OR = 0.65, 95% CI = 0.47–0.91), hypercholesterolemic (OR = 0.75, 95% CI = 0.62–0.91), and obese (OR = 0.41, 95% CI = 0.31–0.54). Migraine without aura was also associated with sCeAD (OR = 1.81, 95% CI = 1.47–2.22) in comparison with patients with non‐CeAD IS. In the subgroup of patients with migraine, patients with sCeAD had higher frequency of migraine attacks and were less likely to take anti‐migraine preventive medications, especially beta‐blockers, compared with the other groups.Interpretation: The risk of sCeAD is influenced by migraine, especially migraine without aura, more than by other factors, increases with increasing frequency of attacks, and seems to be reduced by migraine preventive medications, namely beta‐blockers. ANN NEUROL 2023;94:585–595

6 May 2014 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
DPDaniele Pepe
Daniele Pepe
MGMario Grassi
Mario Grassi
It is currently accepted that the perturbation of complex intracellular networks, rather than the dysregulation of a single gene, is the basis for phenotypical diversity. High-throughput gene expression data allow to investigate changes in gene expression profiles among different conditions. Recently, many efforts have been made to individuate which biological pathways are perturbed, given a list of differentially expressed genes (DEGs). In order to understand these mechanisms, it is necessary to unveil the variation of genes in relation to each other, considering the different phenotypes. In this paper, we illustrate a pipeline, based on Structural Equation Modeling (SEM) that allowed to investigate pathway modules, considering not only deregulated genes but also the connections between the perturbed ones.


7 April 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
VMVincenzo Dario Mandato
Vincenzo Dario Mandato
EFEnrico Farnetti
Enrico Farnetti
FTFederica Torricelli
Federica Torricelli
MAMartino Abrate
Martino Abrate
BCBruno Casali
Bruno Casali
Stefano PalombaStefano Palomba
Stefano Palomba
HNF1B (formerly known as TCF2) gene encodes for a transcription factor that regulates gene expression involved in normal mesodermal and endodermal developments. A close association between rs4430796 polymorphism of HNF1B gene and decreased endometrial cancer (EC) risk has been demonstrated. The aim of the current study was to test the hypothesis that rs4430796 polymorphism can influence the prognosis of EC patients. Retrospective cohort study. Clinical and pathological data were extrapolated and genotypes were assessed on formalin-fixed and paraffin-embedded non-tumour tissues. The influence of patients’ genotype on overall survival and progression free survival were our main outcome measures. A total of 191 EC patients were included in the final analysis. Overall survival differed significantly (P = 0.003) among genotypes. At multivariate analysis, a significant (P < 0.05) effect on overall survival was detected for FIGO stage, and rs4430796 polymorphism of HNF1B gene. After grouping EC patients according to adjuvant treatment, rs4430796 polymorphism resulted significantly (P < 0.001) related to overall survival only in subjects who received radiotherapy plus chemotherapy. A significant (P = 0.014) interaction between rs4430796 polymorphism and chemo-radiotherapy was also detected. Finally, only a trend (P = 0.090) towards significance was observed for rs4430796 polymorphism effect on progression free survival. rs4430796 polymorphism of HNF1B gene influences independently the prognosis of EC patients with a potential effect on tumor chemo-sensitivity.